Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
This PKI news page is best understood in the context of the information provided for Revvity, Inc. (NYSE: RVTY), which appears in the supplied news releases. While PKI historically referred to PerkinElmer in analytical laboratory instrument manufacturing, the current news flow in the input is associated with Revvity, a health science company whose activities span discovery to development, and diagnosis to cure.
The news items describe Revvity as providing health science solutions, technologies, expertise, and services, with focus areas that include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. They also note that Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments, and that it is part of the S&P 500 index with customers in more than 160 countries.
Across the sample releases, typical news topics include quarterly financial results, dividend declarations, product launches in diagnostics and life sciences, and participation in healthcare investor conferences. Examples in the input include announcements of new reagent technologies for drug discovery, reference standards for oncology diagnostic testing workflows, and automated analytical platforms for specialty testing, as well as updates on earnings calls and financial performance.
For users researching PKI, this page therefore functions as an entry point into the more recent narrative presented under Revvity’s RVTY symbol in the provided material. Readers can use the news feed to follow themes such as health science product introductions, diagnostics and life sciences workflow tools, and financial reporting, as reflected in the supplied press releases.
Revvity (NYSE: RVTY) has announced its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on August 8, 2025 to shareholders of record as of the close of business on July 18, 2025.
Revvity (NYSE: RVTY) has scheduled its first quarter 2025 financial results announcement for Monday, April 28, 2025, before market open. The company will hold a conference call at 8:00 a.m. ET on the same day to discuss the results. CEO Prahlad Singh and CFO Max Krakowiak will host the call, which will be accessible via live audio webcast through the Investors section of Revvity's website.
Revvity (NYSE: RVTY) has received FDA approval for its Auto-Pure 2400 liquid handling platform integrated with the T-SPOT.TB test for latent tuberculosis detection. The system, which was initially launched outside the U.S. in 2024, combines automation with high clinical accuracy in TB diagnostics.
The Auto-Pure 2400 platform features automated liquid handling and magnetic cell isolation technology, processing up to 24 samples per run and completing Day 1 testing in under 3.5 hours with minimal user interaction. The T-SPOT.TB test, recognized by WHO as the only ELISPOT-based IGRA, includes a cell number normalization step that ensures consistent results by reducing pre-analytical variables.
Key advantages include fewer indeterminate results, reduced repeat testing requirements, and reliable performance in immunocompromised patients.
Revvity (NYSE: RVTY) has expanded its partnership with Genomics England for the Generation Study, adding DNA sequencing services to their existing DNA extraction services. The collaboration aims to screen up to 100,000 newborns for over 200 rare genetic disorders through whole genome sequencing (WGS).
The company will provide an integrated end-to-end solution with a localized lab facility, enabling faster extraction and sequencing services. This research project, conducted in partnership with the National Health Service, will help inform future decisions on implementing WGS in newborn screening programs, potentially enabling earlier interventions and personalized care for pediatric-onset conditions.
Revvity (NYSE: RVTY) has announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG), expanding its infectious disease diagnostics portfolio. This novel assay is designed to support measles virus infection diagnosis and immune status determination.
The test is notable as the first commercial assay validated for dried blood spots (DBS) alongside traditional serum and plasma samples. DBS testing requires only fingertip blood droplets on paper cards, offering advantages in routine testing, studies, and regions with medical infrastructure.
The assay addresses a market gap as the first commercial solution for detecting anti-measles virus IgG antibodies using DBS samples, eliminating the need for laboratories to conduct their own validations. The test can be processed both manually and automatically using EUROIMMUN's scalable solutions.
Revvity (NYSE: RVTY) has secured a favorable ruling from the Massachusetts Superior Court, which will issue a permanent injunction enforcing its agreements with Cloud Software Group (CSG) regarding Spotfire® software. This follows a preliminary injunction from April 2024 and ensures continued access to Spotfire software and support for Revvity and its customers through 2034.
The ruling maintains Revvity's position as the exclusive provider of Spotfire in research and clinical markets, safeguarding operational continuity and service quality for customers. The company expressed satisfaction with the court's decision to uphold the agreements and emphasized its commitment to maintaining service reliability.
Revvity (NYSE: RVTY) has announced its participation in four major investor conferences during March 2025. The company's leadership team will present at the following events:
- 46th Annual Raymond James Institutional Investor Conference (March 3, 7:30 a.m. ET) featuring CFO Max Krakowiak
- TD Cowen 45th Annual Health Care Conference (March 4, 9:10 a.m. ET) with CEO Prahlad Singh
- Leerink Partners Global Healthcare Conference (March 11, 8:00 a.m. ET) featuring CEO Prahlad Singh
- KeyBanc Capital Markets Healthcare Forum (March 19, 9:00 a.m. ET) with Steve Willoughby, SVP of Investor Relations
The presentations will provide updates on the company's strategic priorities. Live audio webcasts will be available on the company's website, with replays accessible for at least 30 days following the events.
Revvity (NYSE: RVTY) reported strong fourth quarter 2024 results with revenue reaching $729 million, representing 5% reported growth and 6% organic growth. The company's Q4 GAAP EPS was $0.78, while adjusted EPS from continuing operations reached $1.42.
For full year 2024, GAAP revenue was $2,755 million compared to $2,751 million in 2023. The Life Sciences segment reported Q4 revenue of $336 million (5% growth), while Diagnostics segment achieved $393 million (4% growth).
Looking ahead, Revvity initiated its 2025 guidance with projected revenue of $2.80-$2.85 billion and adjusted EPS of $4.90-$5.00.
Revvity (NYSE: RVTY) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on May 9, 2025, to shareholders of record as of the close of business on April 18, 2025.
Revvity (NYSE: RVTY) has announced a strategic agreement with Element Biosciences to develop and commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing. The collaboration combines Revvity's expertise in newborn screening and rare disease detection with Element's AVITI™ sequencing system technology.
The partnership will deliver both an immediate research use only (RUO) version and a comprehensive IVD solution for newborn sequencing. The workflow includes Revvity's sample collection devices, dried blood spot punchers, automated nucleic acid extractors, liquid handlers, NGS library preparation kits with curated NGS panels, and software for variant calling data analysis and interpretation.
This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing workflow for newborn sequencing research and supports Element's progress toward regulatory approval of their benchtop AVITI™ sequencing system.
FAQ
What is the market cap of PERKINELMER (PKI)?
